Clinical trial
Efficacy Study of the Vaginal Gel Carraguard to Prevent HIV Transmission
NCT00213083 · Population Council, Other · Completed
Key facts
| NCT number | NCT00213083 |
|---|---|
| Title | Efficacy Study of the Vaginal Gel Carraguard to Prevent HIV Transmission |
| Official title | Phase 3 Study of the Efficacy and Safety of the Microbicide Carraguard® in Preventing HIV Seroconversion in Women |
| Lead sponsor | Population Council, Other |
| Collaborators | United States Agency for International Development (USAID) U.S. Fed Bill and Melinda Gates Foundation |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections, AIDS, Sexually Transmitted Diseases, HIV Seroconversion |
| Intervention type | Drug |
| Interventions | Carraguard (PC-515) |
| Enrollment | 6,203 |
| Start date | Apr 1, 2004 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Sep 21, 2005 |
| Last update posted | Aug 15, 2017 |
| Countries | South Africa |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: